Table 1.
The demographic and clinical characteristics of the two groups
| Variable | Overall | Remission group | Uncontrolled group | P value |
|---|---|---|---|---|
| Number of patients, n (%) | 105 | 68 (64.8%) | 37 (35.2%) | ‐ |
| Age (y) | 21.5 ± 5.3 | 21.2 ± 5.2 | 22.1 ± 5.3 | 0.375 |
| Gender (female to male) | 57/48 | 37/31 | 20/17 | 0.972 |
| Age of seizure onset (y) | 11.9 ± 4.3 | 11.8 ± 4.6 | 12.1 ± 3.8 | 0.778 |
| Age at diagnosis (y) | 14.5 ± 3.7 | 14.3 ± 3.8 | 14.6 ± 3.7 | 0.683 |
| Duration of epilepsy (y) | 9.6 ± 5.6 | 9.3 ± 5.0 | 10.1 ± 6.7 | 0.490 |
| Follow‐up time (mo) | 47.9 ± 7.2 | 48.2 ± 6.6 | 47.4 ± 8.2 | 0.255 |
| Seizure type | 0.027 | |||
| MS only | 11 | 7 | 4 | |
| MS+GTCS | 72 | 52 | 20 | 0.012 |
| MS+AS | 6 | 1 | 5 | |
| MS+GTCS+AS | 16 | 8 | 8 | |
| Monotherapy/polytherapy | 85/20 | 57/12 | 28/8 | 0.550 |
| Monotherapy (female to male) | ||||
| LEV | 37 (33/4) | 28 | 9 | ‐ |
| VPA | 40 (3/37) | 25 | 15 | ‐ |
| LTG | 3 (2/1) | 1 | 2 | ‐ |
| CBZ | 1 (1/0) | 1 | 0 | ‐ |
| TPM | 4 (3/1) | 2 | 2 | ‐ |
| Polytherapy (female to male) | ||||
| VPA+LEV | 6 (5/1) | 4 | 2 | ‐ |
| LEV+LTG | 1 (1/0) | 1 | 0 | ‐ |
| VPA+LTG | 4 (2/2) | 3 | 1 | ‐ |
| LEV+TPM | 4 (3/1) | 3 | 1 | ‐ |
| LEV+OXC | 3 (3/0) | 0 | 3 | ‐ |
| TPM+VPA+LTG | 1 (0/1) | 0 | 1 | ‐ |
| TPM+VPA+OXC | 1 (1/0) | 0 | 1 | ‐ |
| Median dose (mg, d) | ||||
| VPA | 556.8 | 1250.0 | ‐ | |
| LEV | 629.1 | 1263.9 | ‐ | |
| Seizure‐free, n (%) | ||||
| 3 y | 31/105 (29.5%) | ‐ | ||
| 5 y | 12/82(14.6%) | ‐ | ||
| Family history of epilepsy, n (%) | 4 | 3 (2.9%) | 1 (0.9%) | ‐ |
Remission group = no seizure for at least 1 year.
Abbreviations: AS, absence seizure; CBZ, carbamazepine; GTCS, generalized tonic‐clonic seizure; LEV, levetiracetam; LTG, lamotrigine; MS, myoclonic seizure; OXC, oxcarbazepine; TPM, topiramate; VPA, valproate.